Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)
Open Access
- 27 April 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (8) , 2147-2151
Abstract
Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on an atazanavir-based regimen. We analysed patients failing on an atazanavir-containing regimen used as a first line of PI therapy. We compared the sequences of reverse transcriptase and protease before the introduction of atazanavir and at failure [two consecutive viral loads (VLs) >50 copies/mL]. Resistance was defined according to the 2014 Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) algorithm. Among the 113 patients, atazanavir was used in the first regimen in 71 (62.8%) patients and in the first line of a PI-based regimen in 42 (37.2%). Atazanavir was boosted with ritonavir in 95 (84.1%) patients and combined with tenofovir/emtricitabine or lamivudine (n = 81) and abacavir/lamivudine or emtricitabine (n = 22). At failure, median VL was 3.05 log10 copies/mL and the median CD4+ T cell count was 436 cells/mm3. The median time on atazanavir was 21.2 months. At failure, viruses were considered resistant to atazanavir in four patients (3.5%) with the selection of the following major atazanavir-associated mutations: I50L (n = 1), I84V (n = 2) and N88S (n = 1). Other emergent PI mutations were L10V, G16E, K20I/R, L33F, M36I/L, M46I/L, G48V, F53L, I54L, D60E, I62V, A71T/V, V82I/T, L90M and I93L/M. Emergent NRTI substitutions were detected in 21 patients: M41L (n = 2), D67N (n = 3), K70R (n = 1), L74I/V (n = 3), M184V/I (n = 16), L210W (n = 1), T215Y/F (n = 3) and K219Q/E (n = 2). Resistance to atazanavir is rare in patients failing the first line of an atazanavir-based regimen according to the ANRS. Emergent NRTI resistance-associated mutations were reported in 18% of patients.Keywords
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
This publication has 13 references indexed in Scilit:
- Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN StudyHIV Research & Clinical Practice, 2016
- Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1Annals of Internal Medicine, 2014
- Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1Annals of Internal Medicine, 2011
- Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyThe Lancet, 2008
- Forgiveness of non-adherence to HIV-1 antiretroviral therapyJournal of Antimicrobial Chemotherapy, 2008
- Protease Inhibitor-Based Regimens for HIV TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Identification of I50L as the Signature Atazanavir (ATV)–Resistance Mutation in Treatment‐Naive HIV‐1–Infected Patients Receiving ATV‐Containing RegimensThe Journal of Infectious Diseases, 2004
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2003
- Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2003